Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Products under Development by Stage of Development | 7 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Products under Development by Therapy Area | 8 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Products under Development by Indication | 9 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Products under Development by Companies | 12 | 2 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Therapeutics Assessment | 14 | 4 |
| Assessment by Monotherapy/Combination Products | 14 | 1 |
| Assessment by Mechanism of Action | 15 | 1 |
| Assessment by Route of Administration | 16 | 1 |
| Assessment by Molecule Type | 17 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Companies Involved in Therapeutics Development | 18 | 5 |
| Chipscreen Biosciences Ltd | 18 | 1 |
| GlaxoSmithKline Plc | 19 | 1 |
| HitGen LTD | 20 | 1 |
| NatureWise Biotech &Medicals Corporation | 21 | 1 |
| Sigma-Tau S.p.A. | 22 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Drug Profiles | 23 | 9 |
| HG-3001 Drug Profile | 23 | 1 |
| Largazole Drug Profile | 24 | 1 |
| NBM-01 Drug Profile | 25 | 1 |
| Small Molecule to Inhibit HDAC 8 for Pancreatic Cancer Drug Profile | 26 | 1 |
| Small Molecule to Inhibit Histone Deacetylases for Oncology Drug Profile | 27 | 1 |
| ST-3595 Drug Profile | 28 | 1 |
| tucidinostat Drug Profile | 29 | 3 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Dormant Projects | 32 | 1 |
| Histone Deacetylase 8 (Histone Deacetylase Like 1 or HDAC8 or EC 3.5.1.98) Featured News &Press Releases | 33 | 7 |
| Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team | 33 | 1 |
| Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan | 33 | 1 |
| Sep 03, 2015: HUYA Bioscience International Announces Epigenetic Breast Cancer Program | 33 | 1 |
| Aug 27, 2015: HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting | 34 | 1 |
| Mar 19, 2015: HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan | 35 | 1 |
| Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China | 35 | 1 |
| Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China | 36 | 1 |
| Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation | 36 | 1 |
| Nov 06, 2013: The CSO of Chipscreen Biosciences was invited to speak at The 4th CPA-RSC Symposium on Medicinal Chemistry: Epigenetics as Targets for Drug Discovery | 37 | 1 |
| Apr 16, 2013: Chipscreen Biosciences Announces Achievement Of Primary Endpoint In Chidamide Registrational Phase II Trial In China | 37 | 1 |
| Jul 24, 2012: Chidamide is scheduling to file NDA by the end of this year | 37 | 1 |
| Aug 23, 2010: Chidamide (CS055) obtained permission from SFDA to enter into Phase II and III clinic studies for NSCLC, Breast and Prostate cancer in China | 38 | 1 |
| Jan 23, 2010: Chidamide (CS055) won US FDA nod to enter into clinic trials in the US | 38 | 1 |
| Feb 26, 2009: Chidamide (CS055) won orphan drug designation from SFDA to enter into NDA-directed clinic study for CTCL | 38 | 1 |
| Oct 30, 2008: Chipscreen Biosciences and HUYA Bioscience Announce Promising Preclinical and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000 | 38 | 2 |
| Appendix | 40 | 2 |
| Methodology | 40 | 1 |
| Coverage | 40 | 1 |
| Secondary Research | 40 | 1 |
| Primary Research | 40 | 1 |
| Expert Panel Validation | 40 | 1 |
| Contact Us | 40 | 1 |
| Disclaimer | 41 | 1 |